960308-92-3

Upstream product

• 515131-35-8 4-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzoic acid 
• 124-40-3 dimethyl amine 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 73183-34-3 bis(pinacol)diborane 
• 82998-57-0 3-iodo-4-toluic acid 
• 1019327-29-7 4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoyl chloride 

Relevant academic research and scientific papers

NAPHTHYRIDINES AS INHIBITORS OF HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

NOVEL COMPOUNDS

Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, and 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.

NOVEL COMPOUNDS

Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.

NOVEL COMPOUNDS

Novel substituted l,5,7-trisubstituted-354-dihydro-pyriinido[4,5-(flpyrimidin- 2-(2H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.

PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES

The present invention is directed to a novel method of preparing of 2,4,8- trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (Ha) wherein GHs CH2 Or NH: G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O-S(O)